Document Library
Filter by country
Africa
Angola
Benin
Burkina Faso
Burundi
Cameroon
Central African Republic (the)
Chad
Comoros (the)
Congo (the)
Cote d'Ivoire
Congo, DR
Eritrea
Ethiopia
The Gambia
Ghana
Guinea-Bissau
Guinea
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mozambique
Niger
Nigeria
Rwanda
Sao Tome and Principe
Senegal
Sierra Leone
South Sudan
Tanzania, UR
Togo
Uganda
Zambia
Zimbabwe
South-East Asia
Bangladesh
Bhutan
Korea, DPR
India
Myanmar
Nepal
Sri Lanka
Timor Leste
Americas
Cuba
Haiti
Honduras
Nicaragua
Bolivia
Guyana
Europe
Albania
Armenia
Azerbaijan
Bosnia-Herzegovina
Georgia
Kyrgyzstan
Moldova
Tajikistan
Turkmenistan
Ukraine
Uzbekistan
Western Pacific
Cambodia
China
Indonesia
Kiribati
Lao PDR
Mongolia
Papua New Guinea
Solomon Islands
Vietnam
Eastern Mediterranean
Afghanistan
Djibouti
Pakistan
Somalia
Sudan (the)
Yemen
Filter by type
Country
Africa
South-East Asia
Americas
Europe
Western Pacific
Eastern Mediterranean
Documents
Annual Reports
AMC Documents
Country Documents
Evaluations
Financial Reports
Guidelines and Forms
Legal
Strategy
Supply and Procurement
Policies
White papers
Gavi Fact Sheets
Gavi Publications
The Evidence Base
Gavi Bulletin
Other Publishers
Board Minutes
Committee minutes
Audit
Spanish
Russian
IRC reports
Portuguese
Annual Contributions and Proceeds
Cash Receipts
Advocacy
Resource mobilisation
German
COVID-19 situation report
COVAX documents
COVAX AMC
Gavi Process Guidelines
Gavi Programme Funding Guidelines
Programme audit
Internal audit
Investigation
Reports to the Board
Other (IA)
COVAX data brief
DHI
VIS
News
AMC Updates
Gavi Features
Press Releases
Roi
Statements
Gavi Blogs
Vaccineswork
Theme - Pentavalent
Top stories
3rd donor pledging
3rd donor pledging featured
Partner news
IATI
Social media toolkit
Audio Visual
Infographics
Presentations
Videos
Galleries
Market shaping
Phase I - innovations
Phase II - innovations
VIPS
Gender
Board
Committee
Members
Donor
Japan
Governments EU
Foundations corps orgs
RFP
Country managed evaluations
Old RFP
Centralised evaluations (EAC)
3rd donor pledging announcements
Types of support
Human papillomavirus
Inactivated polio vaccine
Japanese encephalitis
Measles and measles-rubella
Meningitis A
Oral cholera
Pentavalent
Pneumococcal
Rotavirus
Typhoid
Yellow fever
Health system strengthening
Hexavalent
DTP-containing booster
Board meetings
COVAX roll-out
Africa COVAX roll-out
Americas COVAX roll-out
Eastern Mediterranean COVAX roll-out
Europe COVAX roll-out
SE Asia COVAX roll-out
Western Pacific COVAX roll-out
Decentralised Evaluations
Decentralised Evaluations pages
Knowledge Products
Discussion Paper
Annual Evaluation Reports
Other learning products
CSO
CSO news
CSO story
CSO learning brief
Africa
Angola
Benin
Burkina Faso
Burundi
Cameroon
Central African Republic (the)
Chad
Comoros (the)
Congo (the)
Cote d'Ivoire
Congo, DR
Eritrea
Ethiopia
The Gambia
Ghana
Guinea-Bissau
Guinea
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mozambique
Niger
Nigeria
Rwanda
Sao Tome and Principe
Senegal
Sierra Leone
South Sudan
Tanzania, UR
Togo
Uganda
Zambia
Zimbabwe
South-East Asia
Bangladesh
Bhutan
Korea, DPR
India
Myanmar
Nepal
Sri Lanka
Timor Leste
Americas
Cuba
Haiti
Honduras
Nicaragua
Bolivia
Guyana
Europe
Albania
Armenia
Azerbaijan
Bosnia-Herzegovina
Georgia
Kyrgyzstan
Moldova
Tajikistan
Turkmenistan
Ukraine
Uzbekistan
Western Pacific
Cambodia
China
Indonesia
Kiribati
Lao PDR
Mongolia
Papua New Guinea
Solomon Islands
Vietnam
Eastern Mediterranean
Afghanistan
Djibouti
Pakistan
Somalia
Sudan (the)
Yemen
Annual Reports
AMC Documents
Manufacturers related
Strategic Demand Forecast
Target Product Profile
Legal Agreements
Remaining offer amount
Country Documents
Approved proposals
Comprehensive multi-year plans, Financial sustainability plans, National Immunisation Strategy
Country co-financing information sheet
Data quality audit
Decision Letters and Partnerships Agreement
The joint appraisal report and Multi-Stakeholder Dialogue
Targeted country assistance plans
HSS evaluation
HSS tracking study
Annual progress reports
COVAX Technical Assistance Plans
Evaluations
CSO 2012
Full country evaluations
Second evaluation
IFFIm evaluation
HSS evaluation
TCA
Other studies
CSO 2018
Financial Reports
Guidelines and Forms
General
Japanese encephalitis vaccine
Meningitis A vaccine
Pneumococcal vaccine
Rotavirus vaccine
Typhoid vaccine
Yellow fever vaccine
HSS support
CCEOP support
Report on and renew support
TCA
Additional guidance
Joint appraisals
Tools and templates
Legal
Strategy
Phase 4
Phase 5
Phase 3
Phase 2
Phase 1
Risk
Supply and Procurement
Roadmaps
Base demand forecast
Detailed product profiles
Strategy 2016-20
Policies
Corporate
Programmatic
White papers
Gavi Fact Sheets
Gavi Publications
Japanese
Gavi progress reports
Arabic
Investment opportunity
The Evidence Base
Gavi Bulletin
Other Publishers
Board Minutes
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Decisions
Programme
2020
2021
2022
2023
2024
2025
2026
Committee minutes
PPC
EAC
IC
AFC
GC
Audit
Spanish
Russian
IRC reports
Portuguese
Annual Contributions and Proceeds
Cash Receipts
Advocacy
Resource mobilisation
German
COVID-19 situation report
COVAX documents
COVAX AMC
COVAX AMC VR
COVAX AMC TA
COVAX AMC CCE
COVAX AMC CDS (EA)
COVAX AMC CDS (NB)
Legal 1
Legal 2
Gavi Process Guidelines
Human papillomavirus vaccine
Measles and measles-rubella vaccines
Application Process
Application Kit
Analysis
Vaccine Information & Switches
Ongoing Portfolio Management, Reporting & Renewals
Financial Management & Reporting
Joint-Appraisal & Multi Stakeholder Dialogue
IPV
Meningococcal vaccines
Pneumococcal vaccine
Rotavirus vaccine
Typhoid vaccine
Yellow fever vaccine
Malaria vaccine
Cholera vaccine (OCV)
Gavi process guidelines 5.0
Vaccine switch information
Hexavalent guidelines
Ebola
Human rabies vaccine for post-exposure prophylasis
DTP guidelines
Gavi process guidelines 6.0
Gavi Programme Funding Guidelines
Zero-dose
Maintain, Restore & Strengthen
Demand, Communities and Gender
Supply Chain & Cold Chain Equipment
Data
Leadership, Management and Coordination
Immunisation Financing
Gavi Programme Funding Guidelines – Main
Additional Resources
Programme audit
Internal audit
Investigation
Reports to the Board
Other (IA)
COVAX data brief
DHI
Case studies & technical briefs
Practical guides
Digital Health Information Strategy
Research publications
VIS
VIS 2018
AMC Updates
Gavi Features
Press Releases
COVAX latest
Gavi partner
Roi
Statements
Gavi Blogs
Vaccineswork
Primary health care
Universal health care
Equity
Gender
Outbreaks
Technology and innovation
Antimicrobial resistance
Climate change
Urbanisation
Identity
Opinions
Country stories
COVID-19
Most read
Review
Partner
Featured VW articles
Featured Large VW article
MTR
Theme - Pentavalent
Top stories
HEHR
3rd donor pledging
Alliance partners
3rd donor pledging featured
Partner news
IATI
Social media toolkit
Angola
Benin
Burkina Faso
Burundi
Cameroon
Central African Republic (the)
Chad
Comoros (the)
Congo (the)
Cote d'Ivoire
Congo, DR
Eritrea
Ethiopia
The Gambia
Ghana
Guinea-Bissau
Guinea
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mozambique
Niger
Nigeria
Rwanda
Sao Tome and Principe
Senegal
Sierra Leone
South Sudan
Tanzania, UR
Togo
Uganda
Zambia
Zimbabwe
Manufacturers related
Strategic Demand Forecast
Target Product Profile
Legal Agreements
Remaining offer amount
Approved proposals
Approved proposals
Comprehensive multi-year plans, Financial sustainability plans, National Immunisation Strategy
Comprehensive multi-year plans, Financial sustainability plans, National Immunisation Strategy
Country co-financing information sheet
Country co-financing information sheet
Data quality audit
Data quality audit
Decision Letters and Partnerships Agreement
Decision Letters and Partnerships Agreement
The joint appraisal report and Multi-Stakeholder Dialogue
The joint appraisal report and Multi-Stakeholder Dialogue
Targeted country assistance plans
Targeted country assistance plans
HSS evaluation
HSS evaluation
HSS tracking study
HSS tracking study
Annual progress reports
Annual progress reports
COVAX Technical Assistance Plans
COVAX Technical Assistance Plans
CSO 2012
Full country evaluations
FCE 2016
FCE 2015
FCE 2014
FCE 2013
Second evaluation
IFFIm evaluation
HSS evaluation
Gavi managed evaluations
Summaries
TCA
Other studies
CSO 2018
General
Japanese encephalitis vaccine
Meningitis A vaccine
Pneumococcal vaccine
Rotavirus vaccine
Typhoid vaccine
Yellow fever vaccine
HSS support
CCEOP support
Report on and renew support
Tools and templates
Additional info
TCA
Additional guidance
Financial management
Programming guidance
Requirements for implementation
Gender related barriers
Immunisation financing
Leadership management coordination
Improving data quality
Joint appraisals
Tools and templates
Phase 4
Phase 5
Phase 3
Phase 2
Phase 1
Risk
Roadmaps
Vaccine roadmap
CCE roadmap
Diagnostics roadmaps
Base demand forecast
Detailed product profiles
Strategy 2016-20
COVAX latest
Gavi partner
Corporate
Programmatic
Infographics
Presentations
Videos
Galleries
Japanese
Gavi progress reports
Arabic
Investment opportunity
Primary health care
Universal health care
Equity
Gender
Outbreaks
Technology and innovation
Antimicrobial resistance
Climate change
Urbanisation
Identity
Opinions
Seth Berkley
Ngozi Okonjo-Iweala
Anuradha Gupta
Sania Nishtar
Country stories
COVID-19
Explainer
Blog
Key news
COVAX
COVAX AMC articles
Most read
1 Trending
2 Trending
3 Trending
4 Trending
5 Trending
6 Trending
Review
Partner
Featured VW articles
Featured Large VW article
MTR
Phase I - innovations
Phase II - innovations
VIPS
Vaccine roadmap
CCE roadmap
Diagnostics roadmaps
Bangladesh
Bhutan
Korea, DPR
India
Myanmar
Nepal
Sri Lanka
Timor Leste
Cuba
Haiti
Honduras
Nicaragua
Bolivia
Guyana
Albania
Armenia
Azerbaijan
Bosnia-Herzegovina
Georgia
Kyrgyzstan
Moldova
Tajikistan
Turkmenistan
Ukraine
Uzbekistan
Cambodia
China
Indonesia
Kiribati
Lao PDR
Mongolia
Papua New Guinea
Solomon Islands
Vietnam
2019
26 June
26 June Presentations
4 Dec
4 Dec presentations
2018
6 June
28 Nov OLD
6 June presentations
28 Nov presentations
28 Nov
28 Nov Pre-Board briefings
6 June pre-board briefings
28 Nov NEW
2017
14 June
7 July
29 Nov
14 June presentations
29 Nov presentations
29 Nov NEW
14 June Tech briefings
14 June NEW
2016
22 June
7 Dec
22 June presentations
7 Dec presentations
22 June Tech briefings
2015
10 June
2 Dec
10 June presentations
2 Dec presentations
2 Dec Tech briefings
10 June Tech briefings
2014
18 June
10 Dec
18 June presentations
10 Dec presentations
10 Dec Tech briefings
18 June Tech briefings
2013
11 June
21 Nov
11 June presentations
21 Nov presentations
2012
12 June
4 Dec
12 June presentations
4 Dec presentations
2011
7 July
16 Nov
7 July presentations
16 Nov presentations
2010
16 June
30 Nov
16 June presentations
30 Nov presentations
2009
Decisions
Programme
Governance
Investment
Audit
Evaluation
2020
19 March
11 May
24 June
24 June presentations
30 July
30 July Presentations
29 Sept
29 Sept Presentations
15-17 Dec
15-17 Dec Presentations
2021
22 March
22 March Presentations
23-24 June
23-24 June Presentations
28 Sept
28 Sept Presentations
30 Nov - 2 Dec
30 Nov - 2 Dec Presentations
Board Decision
2022
22-23 June
22-23 June Presentations
7-8 December
7-8 December Presentations
Board Decision
2023
Board Decision
26-27 June
26-27 June Presentations
6-7 December
6-7 December Presentations
2024
6-7 June
6-7 June Presentations
Board Decision
4-5 December
4-5 December Presentations
2025
24-25 July
24-25 July Presentations
Board Decision
3-4 December
3-4 December Presentations
2026
1-2 July
1-2 July Presentations
Board Decision
26 June
26 June Presentations
4 Dec
4 Dec presentations
6 June
28 Nov OLD
6 June presentations
28 Nov presentations
28 Nov
28 Nov Pre-Board briefings
6 June pre-board briefings
28 Nov NEW
14 June
7 July
29 Nov
14 June presentations
29 Nov presentations
29 Nov NEW
14 June Tech briefings
14 June NEW
22 June
7 Dec
22 June presentations
7 Dec presentations
22 June Tech briefings
10 June
2 Dec
10 June presentations
2 Dec presentations
2 Dec Tech briefings
10 June Tech briefings
18 June
10 Dec
18 June presentations
10 Dec presentations
10 Dec Tech briefings
18 June Tech briefings
11 June
21 Nov
11 June presentations
21 Nov presentations
12 June
4 Dec
12 June presentations
4 Dec presentations
7 July
16 Nov
7 July presentations
16 Nov presentations
16 June
30 Nov
16 June presentations
30 Nov presentations
PPC
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2025
2026
EAC
2009
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2020
2021
2022
2023
2024
2025
IC
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2026
AFC
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2025
2026
GC
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2025
2026
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2025
2026
2009
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2020
2021
2022
2023
2024
2025
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2026
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
2022
2023
2024
2025
2026
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2020
2021
Recommendation
2022
Recommendation
2023
Recommendation
2024
Recommendation
2025
2026
Recommendation
Seth Berkley
Ngozi Okonjo-Iweala
Anuradha Gupta
Sania Nishtar
Committee
Members
Japan
Governments EU
Foundations corps orgs
Tools and templates
Additional info
Financial management
Programming guidance
Requirements for implementation
Gender related barriers
Immunisation financing
Leadership management coordination
Improving data quality
Governance
Investment
Audit
Evaluation
Afghanistan
Djibouti
Pakistan
Somalia
Sudan (the)
Yemen
FCE 2016
FCE 2015
FCE 2014
FCE 2013
Gavi managed evaluations
Summaries
HEHR
Alliance partners
Explainer
Blog
Key news
COVAX
COVAX key articles
COVAX AMC articles
Human papillomavirus
Inactivated polio vaccine
Japanese encephalitis
Measles and measles-rubella
Meningitis A
Oral cholera
Pentavalent
Pneumococcal
Rotavirus
Typhoid
Yellow fever
Health system strengthening
Hexavalent
DTP-containing booster
19 March
11 May
24 June
24 June presentations
30 July
30 July Presentations
29 Sept
29 Sept Presentations
15-17 Dec
15-17 Dec Presentations
1 Trending
2 Trending
3 Trending
4 Trending
5 Trending
6 Trending
COVAX key articles
COVAX AMC VR
COVAX AMC TA
COVAX AMC CCE
COVAX AMC CDS (EA)
COVAX AMC CDS (NB)
Legal 1
Legal 2
Africa COVAX roll-out
Americas COVAX roll-out
Eastern Mediterranean COVAX roll-out
Europe COVAX roll-out
SE Asia COVAX roll-out
Western Pacific COVAX roll-out
22 March
22 March Presentations
23-24 June
23-24 June Presentations
28 Sept
28 Sept Presentations
30 Nov - 2 Dec
30 Nov - 2 Dec Presentations
Board Decision
Recommendation
Human papillomavirus vaccine
Measles and measles-rubella vaccines
Application Process
Application Kit
FPP Application Guidelines & Materials
Standalone EAF Application Materials & Guidelines
Standalone Vaccine Application Materials & Guidelines
Standalone TCA Application Materials & Guidelines
Standalone CCEOP Application Materials & Guidelines
Standalone Innovation Top-up Application Materials & Guidelines
Gavi Middle Income Countries (MICs)
Analysis
Vaccine Information & Switches
Ongoing Portfolio Management, Reporting & Renewals
Financial Management & Reporting
Joint-Appraisal & Multi Stakeholder Dialogue
IPV
Meningococcal vaccines
Pneumococcal vaccine
Rotavirus vaccine
Typhoid vaccine
Yellow fever vaccine
Malaria vaccine
Cholera vaccine (OCV)
Gavi process guidelines 5.0
Vaccine switch information
Hexavalent guidelines
Ebola
Human rabies vaccine for post-exposure prophylasis
DTP guidelines
Gavi process guidelines 6.0
Gavi 6.0 application kit
FPP Application Guidelines & Materials
Standalone EAF Application Materials & Guidelines
Standalone Vaccine Application Materials & Guidelines
Standalone TCA Application Materials & Guidelines
Standalone CCEOP Application Materials & Guidelines
Standalone Innovation Top-up Application Materials & Guidelines
Gavi Middle Income Countries (MICs)
Zero-dose
Maintain, Restore & Strengthen
Demand, Communities and Gender
Supply Chain & Cold Chain Equipment
Data
Leadership, Management and Coordination
Immunisation Financing
Gavi Programme Funding Guidelines – Main
Additional Resources
Discussion Paper
22-23 June
22-23 June Presentations
7-8 December
7-8 December Presentations
Board Decision
Recommendation
Board Decision
26-27 June
26-27 June Presentations
6-7 December
6-7 December Presentations
Recommendation
Case studies & technical briefs
Practical guides
Digital Health Information Strategy
Research publications
VIS 2018
6-7 June
6-7 June Presentations
Board Decision
4-5 December
4-5 December Presentations
Recommendation
CSO news
CSO story
CSO learning brief
24-25 July
24-25 July Presentations
Board Decision
3-4 December
3-4 December Presentations
Gavi 6.0 application kit
1-2 July
1-2 July Presentations
Board Decision
Recommendation
00a Document List As of 24 June pdf
1
Board -2026 -Mtg -02-Doc 00a
Gavi Alliance Board Meeting
1-2 July 2026
Global Health Campus, Geneva, Switzerland
Wednesday 1 July : 09. 00-1 8.0 0 Board Meeting Day One
Thursday 2 July: 08.30-17.00 Board Meeting Day Two
Quorum: 14
Document List
No. Document
00a Document list
00b Agenda
01a Declarations of interest
01b Minutes from 3-4 December 2025
01c No Objection Consent Decisions
01d Consent Agenda
01e Board W orkplan
01f Chair’s remarks
02a CEO’s report
02b Strategy, Programmes and Partnerships
Update: Progress, Risks and
Challenges
03 Committee Chair and IFFIm Board reports
04 Joint Alliance update
05 Resource Mobilisation update
06a Amendment and utilisation of the European Investment Bank (EIB) Frontloading
Facility
06b African Vaccine Manufacturing Accelerator (AVMA)
07 Financial Update, incl uding forecast
08 Gavi Risk Appetite Statement
2
Board -2026 -Mtg -02-Doc 00a
09 Vaccine Budget Policy
10 Health Systems and Immunisation Strengthening Policy
11 Strategic Approach on Campaign Optimisation
12 Fragile and Humanitarian Approach
13 Ukraine Fragility Support
14 Gavi 6.0 Measurement Framework Targets
15 Collaboration with T
he Global Fund to Fight AIDS, Tuberculosis and Malaria
(‘The Global Fund’)
16 Review of decisions – No paper
17 Any other business and Closing remarks – No paper
No. Additional Documents for Information (on BoardEffect)
A Board and Committee minutes (For information only)
Board -2026 -Mtg -02-Doc 00a
Gavi Alliance Board Meeting
1-2 July 2026
Global Health Campus, Geneva, Switzerland
Wednesday 1 July : 09. 00-1 8.0 0 Board Meeting Day One
Thursday 2 July: 08.30-17.00 Board Meeting Day Two
Quorum: 14
Document List
No. Document
00a Document list
00b Agenda
01a Declarations of interest
01b Minutes from 3-4 December 2025
01c No Objection Consent Decisions
01d Consent Agenda
01e Board W orkplan
01f Chair’s remarks
02a CEO’s report
02b Strategy, Programmes and Partnerships
Update: Progress, Risks and
Challenges
03 Committee Chair and IFFIm Board reports
04 Joint Alliance update
05 Resource Mobilisation update
06a Amendment and utilisation of the European Investment Bank (EIB) Frontloading
Facility
06b African Vaccine Manufacturing Accelerator (AVMA)
07 Financial Update, incl uding forecast
08 Gavi Risk Appetite Statement
2
Board -2026 -Mtg -02-Doc 00a
09 Vaccine Budget Policy
10 Health Systems and Immunisation Strengthening Policy
11 Strategic Approach on Campaign Optimisation
12 Fragile and Humanitarian Approach
13 Ukraine Fragility Support
14 Gavi 6.0 Measurement Framework Targets
15 Collaboration with T
he Global Fund to Fight AIDS, Tuberculosis and Malaria
(‘The Global Fund’)
16 Review of decisions – No paper
17 Any other business and Closing remarks – No paper
No. Additional Documents for Information (on BoardEffect)
A Board and Committee minutes (For information only)
00b Board 2026 Mtg 02 Agenda as of 15 June 2026 pdf
Board-2026-Mtg -0 2-Doc 00b
1
Gavi Alliance Board Meeting
1-2 Ju ly 202 6
Global Health Campus , Geneva, Switzerland
Monday 29 June: Pre -Board meetings
Tuesday 30 June: Pre-Board meetings and Technical Briefings
Wednesday 1 July : 09. 00-1 8.0 0 Board Meeting Day One
Thursday 2 July : 08.30 -17.00 Board Meeting Day Two
Quorum: 14
A genda
as of 15 June 2026
Next Board Meeting: 9-10 December 2026
17-18 March 2027 (Board Retreat)
30 June-1 July 2027
1-2 December 2027
---
Brenda Killen , Director, Governance and Secretary to the Board
Melissa Wolfe, Head, Governanc e
Governance@gavi.org
Please note that the Board meeting will be recorded and transcripted. Th e recording and transcript will be
used as an aid to minute the meeting.
Board-2026-Mtg -0 2-Doc 00b
2
Pre -Board Meetings – Monday 29 June 2026
Schedule Meeting Room
09. 10-1 0.3 0 o Human Resources Subcommittee meeting Marula
12.00- 14.4 0 o Governance Committee meeting Banyan
15.00- 16.00 o Unaffiliated Recruitment Subcommittee meeting Marula
Board Briefings / Pre-Board Meetings –Tuesday 30 June 2026
Schedule Meeting Room
10.00- 11.00 o Meeting of IFFIm Donors Banyan
10.00- 12.00 o Meeting of Gavi Implementing Country Caucus Baobab
11. 00- 12.00
o Meeting of Gavi Donor Constituency Banyan
11.00- 12.00 o All Chairs Group Marula
12.30- 14.30 o Joint Gavi -Global Fund Technical Briefing Forum
15.00- 18.00 o Closed Session: For Board Members and Alternate Board Members
only *DECISION* Forum
18.30- 19.30 o Joint Gavi Implementing Country Caucus and Donor Constituency
Meeting Banyan
01b Board 2025 Mtg 03 Minutes POSTED pdf
Board-2025-Mtg -03
1
Minutes
Gavi Alliance Board Meeting
3-4 December 2025
Geneva , Switzerland
1. Chair’s report
1.1 Noting that the meeting had been duly convened and finding a quorum of
members present, the meeting commenced at 10 :2 0 Geneva time on
3 December 202 5. Prof essor José Manuel Barroso, Board Chair, chaired the
meeting.
1.2 The Chair welcomed new Board and Alternate members attending their first
Board meeting, namely: Syed Mustafa Kamal, Leone Gianturco, Marit Viktoria
Pettersen, Kristen Chenier and Iin Susanti .
1.3 Standing declarations of interest were tabled to the Board (Doc 01a in the Board
pack).
1.4 The Board noted its minutes from 24-2 5 July 202 5 (Doc 01b) which were
approved by no objection on 19 November 2025 .
1.5 The Chair referred to the consent agenda (Doc 01d ) where five
recommendations were presented for consideration. At the request of the Chair,
Brenda Killen, Director, Governance and Secretary to the Board, presented the
consent agenda decisions.
1.6 The Chair noted the Board workplan (Doc 01 e).
1.7 The Chair reported that during the closed session on the morning of 3
December 202 5, the Board heard from the Gavi CEO, Dr Sania Nishtar, on the
joint Gavi -Global Fund Task Force.
1.8 The Chair also reported on his recent travel , and referred to several preparatory
meetings that took place in the lead to the Board, including the joint Global Polio
Eradication Initiative (GPEI ) and Gavi Board meeting, an informal Market -
Sensitive Decision s Committee ( MSDC) meeting to help finalise the Gavi 6.0
Market Shaping Strategy risks , as well as the technical briefing on the Gavi 6.0
Country Vaccine Budgets (CVBs).
Decision 1
The Gavi Alliance Board:
Approved to waive the requirement for an independent review for the reprogramming
and no-cost extension of HSS funding for countries with existing IRC approvals to
support their transition into consolidated funding levers and aligned grant cycles in
2026.
01d Annex A Market Shaping Strategy 2026 2030 pdf
PPC -2026 -Mtg -01 -Doc 05b -Annex A 1
Report to the Programme and Policy Committee
12 -13 May 2026
Annex A : Gavi Market Shaping Strategy 2026 -2030
Table of Contents
Executive summary ................................ ................................ ................................ .. 2
The Market Shaping model ................................ ................................ ...................... 4
Market shaping in the context of Gavi ................................ ................................ ................... 4
The Market Shaping Strategy 6.0 ................................ ................................ .......................... 5
Strategic Goal 4 (SG4) – “Ensure healthy markets for vaccines and related
products” ................................ ................................ ................................ .................. 7
Gavi 6.0 framework and policies ................................ ................................ ............. 8
Market Shaping Strategy: strategic priorities and target outcomes ....................... 10
SP1 - Optimise vaccine programme affordability to countries and Gavi .............................. 11
SP2 - Maintain supply access, security, and market heath ................................ .................. 12
SP3 - Develop future markets for VIS -endorsed and outbreak, epidemic and pandemic
(OEP) vaccines. ................................ ................................ ................................ .................. 15
Market Shaping Strategy: enablers ................................ ................................ ...... 16
Healthy demand ................................ ................................ ................................ .................. 17
Alliance collaboration ................................ ................................ ................................ .......... 18
Market Shaping roadmaps and analytical support ................................ ............................... 20
Implementation mechanisms ................................ ................................ ............................... 22
Decision -making pathways ................................ ................................ ................................ . 27
Monitoring and evaluation framework ................................ ................................ .. 29
Case studies – Strategy to action ................................ ................................ ......... 31
01e Board Workplan As at 15 June 2026 pdf
Classified as Internal #
Gavi Alliance Board Workplan
Gavi Board Paper July Dec Mar/Apr June Nov/Dec Mar/Apr June Nov/Dec
A.Strategy/Performance/Risk/MEL CEO's Report CEO's Report Discussion Discussion Discussion Discussion Discussion Discussion 2021-2025 Strategy Strategy, Programmes and Partnerships: Progress, Risks and Challenges Discussion Market Shaping Retrospective Strategy, Programmes and Partnerships: Progress, Risks and Challenges Information Foundational Fund Strategy, Programmes and Partnerships: Progress, Risks and Challenges Discussion Discussion Discussion Discussion Discussion Discussion Private Sector and Innovation Strategy TBD Decision Risk and Assurance Report Risk and Assurance Report Decision Decision Decision 2026-2030 StrategyStrategy, Programmes and Partnerships: Progress, Risks and Challenges Discussion Discussion Discussion Discussion Discussion Discussion Vaccine BudgetsVaccine Budget PolicyDecision6.0 Measurement Framework (targets) Gavi 6.0 Measurement Framework Decision Market Shaping Strategy Consent Agenda DecisionFragile & Humanitarian Approach update Fragile & Humanitarian Approach Decision B.Vaccines & SustainablityTyphoid TBD Pneumococcal AMC (Advance Market Commitment) TBD Vaccine Investment Strategy Vaccine Investment Strategy Decision Decision Gavi's role in Global Health Security GHS 6.0 Vision and Approach (PPPR) - TBD For Information (Dec)
InformationDay Zero Facility - First Response Fund (Annual Report provided for information as appendix) Annex to TBD or as an appendix Information Information Information African Vaccine Manufacturing Accelerator AVMA Decision Information Information Information VaccinesMalaria TBD Information Information Information Information Information Information HPV SPP Paper, Annex Information Information Ebola TBD Yellow Fever TBD Mpox TBD RSV mAbs Revised Investment Case Decision Dengue Revised Investment Case Decision Tuberulosis Revised Investment case (2029) Guidance HepE Revised Investment Case Decision C.PolicyTransparency and Accountability Policy TBD Fragility, Emergencies and Refugees Policy TBD Prioritisation Mechanism for Gavi's Support to Countries TBD Evaluation Policy TBD Decision Speak Up Policy TBD Donations / Gift Policy TBD Decision Vaccine Procurement Policy TBD - subset of Market Shaping Strategy Guidance Decision Vaccine Donations Policy GHS 6.0 Vision and Approach Guidance Decision D.Country ProgrammesJoint Alliance Update on Country Programmes Joint Alliance Update Discussion Discussion Discussion Discussion Discussion Discussion Fragility Support to Ukraine Ukraine Fragility Support Decision E.Finance/Audit & InvestigationsAnnual Accounts Annual Financial Report No-objection Decision Decision Financial Forecast Financial Update, including forecast Decision Decision Decision Decision Decision Decision Fundational Fund and Secretariat BudgetFinancial Update, including forecast DecisionDecisionDecisionProgramme Funding Policy TBD Treasury Governance Policy TBDTreasury Risk Management Policy TBD Independent Auditor Selection and Evaluation Policy TBD Audit & Investigations Report Audit & Investigations Report Information Information Information F.Governance Board Chair Appointment Consent Agenda Decision Board Vice Chair Appointment Consent Agenda Decision Decision Committee Chair Appointments Consent Agenda Decision Decision Board and Committee Appointments Consent Agenda Decision Decision IRC Appointments Consent Agenda Decision CEO Appointment Consent Agenda Secretary Appointment Consent Agenda Treasurer Appointment Consent Agenda Appointment of MD A&I Consent AgendaAmendments to Governance Documents (Statutes, By-Laws, Committee Charters) Consent Agenda Decision IRC Terms of Reference TBD Audit & Investigations Terms of Reference Consent Agenda Update on collaboration with other Organisations Collaboration with The Global Fund Information HR Sub-Committee TBD G.ReportingCommittee Chair Reports Committee Chair and IFFIm Board reports Information Information Information Information Information Information IFFIm Chair Reports Committee Chair and IFFIm Board reports Information Information Information Information Information Information Replenishment/Resource Mobilisaton Resource Mobilisation Update Information HR Report Closed Session Information Information Information Information Annual Report on Implementation of the Gender Policy Annex to Strategy paper Information Information Information Board and Committee minutes Annex to Board pack/On BE as additional materials Information Information Information Information Information Information H. Technical Briefing Sessions/Deep DivesGavi Leap (including Grant Management Reform, CVBs) Jun-26 Information Gavi Global Fund Task Force Jun-26 Information Vaccine Safety Narratives and Misinformation Pre-Retreat Briefings
2028
2026 2027
Last updated - 15 June 2026
Next Board Meetings: 9-10 December 2026 \
17-18
Gavi Alliance Board Workplan
Gavi Board Paper July Dec Mar/Apr June Nov/Dec Mar/Apr June Nov/Dec
A.Strategy/Performance/Risk/MEL CEO's Report CEO's Report Discussion Discussion Discussion Discussion Discussion Discussion 2021-2025 Strategy Strategy, Programmes and Partnerships: Progress, Risks and Challenges Discussion Market Shaping Retrospective Strategy, Programmes and Partnerships: Progress, Risks and Challenges Information Foundational Fund Strategy, Programmes and Partnerships: Progress, Risks and Challenges Discussion Discussion Discussion Discussion Discussion Discussion Private Sector and Innovation Strategy TBD Decision Risk and Assurance Report Risk and Assurance Report Decision Decision Decision 2026-2030 StrategyStrategy, Programmes and Partnerships: Progress, Risks and Challenges Discussion Discussion Discussion Discussion Discussion Discussion Vaccine BudgetsVaccine Budget PolicyDecision6.0 Measurement Framework (targets) Gavi 6.0 Measurement Framework Decision Market Shaping Strategy Consent Agenda DecisionFragile & Humanitarian Approach update Fragile & Humanitarian Approach Decision B.Vaccines & SustainablityTyphoid TBD Pneumococcal AMC (Advance Market Commitment) TBD Vaccine Investment Strategy Vaccine Investment Strategy Decision Decision Gavi's role in Global Health Security GHS 6.0 Vision and Approach (PPPR) - TBD For Information (Dec)
InformationDay Zero Facility - First Response Fund (Annual Report provided for information as appendix) Annex to TBD or as an appendix Information Information Information African Vaccine Manufacturing Accelerator AVMA Decision Information Information Information VaccinesMalaria TBD Information Information Information Information Information Information HPV SPP Paper, Annex Information Information Ebola TBD Yellow Fever TBD Mpox TBD RSV mAbs Revised Investment Case Decision Dengue Revised Investment Case Decision Tuberulosis Revised Investment case (2029) Guidance HepE Revised Investment Case Decision C.PolicyTransparency and Accountability Policy TBD Fragility, Emergencies and Refugees Policy TBD Prioritisation Mechanism for Gavi's Support to Countries TBD Evaluation Policy TBD Decision Speak Up Policy TBD Donations / Gift Policy TBD Decision Vaccine Procurement Policy TBD - subset of Market Shaping Strategy Guidance Decision Vaccine Donations Policy GHS 6.0 Vision and Approach Guidance Decision D.Country ProgrammesJoint Alliance Update on Country Programmes Joint Alliance Update Discussion Discussion Discussion Discussion Discussion Discussion Fragility Support to Ukraine Ukraine Fragility Support Decision E.Finance/Audit & InvestigationsAnnual Accounts Annual Financial Report No-objection Decision Decision Financial Forecast Financial Update, including forecast Decision Decision Decision Decision Decision Decision Fundational Fund and Secretariat BudgetFinancial Update, including forecast DecisionDecisionDecisionProgramme Funding Policy TBD Treasury Governance Policy TBDTreasury Risk Management Policy TBD Independent Auditor Selection and Evaluation Policy TBD Audit & Investigations Report Audit & Investigations Report Information Information Information F.Governance Board Chair Appointment Consent Agenda Decision Board Vice Chair Appointment Consent Agenda Decision Decision Committee Chair Appointments Consent Agenda Decision Decision Board and Committee Appointments Consent Agenda Decision Decision IRC Appointments Consent Agenda Decision CEO Appointment Consent Agenda Secretary Appointment Consent Agenda Treasurer Appointment Consent Agenda Appointment of MD A&I Consent AgendaAmendments to Governance Documents (Statutes, By-Laws, Committee Charters) Consent Agenda Decision IRC Terms of Reference TBD Audit & Investigations Terms of Reference Consent Agenda Update on collaboration with other Organisations Collaboration with The Global Fund Information HR Sub-Committee TBD G.ReportingCommittee Chair Reports Committee Chair and IFFIm Board reports Information Information Information Information Information Information IFFIm Chair Reports Committee Chair and IFFIm Board reports Information Information Information Information Information Information Replenishment/Resource Mobilisaton Resource Mobilisation Update Information HR Report Closed Session Information Information Information Information Annual Report on Implementation of the Gender Policy Annex to Strategy paper Information Information Information Board and Committee minutes Annex to Board pack/On BE as additional materials Information Information Information Information Information Information H. Technical Briefing Sessions/Deep DivesGavi Leap (including Grant Management Reform, CVBs) Jun-26 Information Gavi Global Fund Task Force Jun-26 Information Vaccine Safety Narratives and Misinformation Pre-Retreat Briefings
2028
2026 2027
Last updated - 15 June 2026
Next Board Meetings: 9-10 December 2026 \
17-18
01f Chair s remarks No paper pdf
1
Board-2026-Mtg- 02-Doc 01f
Report to the Board
1-2 July 2026
Subject Chair’s remarks
Agenda item 01f
No paper
Verbal update at meeting.
Board-2026-Mtg- 02-Doc 01f
Report to the Board
1-2 July 2026
Subject Chair’s remarks
Agenda item 01f
No paper
Verbal update at meeting.
02a Annex A EN Reform Table pdf
Board-2026-Mtg- 02-Doc 02a- Annex A 1
Report to the Board
1- 2 July 2026
Annex A
Topic /
Sub -topic
How was it before the
change
Reforms already implemented Results achieved Next steps
1) SECRETARIAT MANAGEMENT POLICIES
1.1 Policy
repository &
hygiene
• 190+ internal guidance
documents
• No central archive and
visibility of which
instrument is being used
for decision making
• Policy overlaps
• Operational Policy Repository has
been established consolidating all
internal guidance documents into one
archive to bring transparency.
• External assessments have been
undertaken to outline gaps, and major
efforts have been undertaken to revise
key operational policies, in particular,
to bolster checks and balances (e.g.,
Procurement Policy, Human Resource
policy, and others outlined below in
1.2).
• Policy hygiene workplan was
launched to approve, sunset, merge,
policies as appropriate.
• “ Policy on Policies” has been
developed to guide the further course.
• From 2024 onwards a process was
established (See secretariat
management Sub- group below)
• A transparent system is
now in place to oversee
the development and
approval of secretariat
operational policies; this
has increased
transparency and has
ushered in consistency in
the approach to
developing and approving
secretariat policies.
• It also enabled clarity on
which instruments are
being used for decision-
making, opportunities for
course correction, and it
reduced policy overlaps
and the overall the
number of internal
• Resources have
been approved
to move the
Policy
Repository into
a digital tool
02a Annex A FR Reform Table pdf
Board-2026-Mtg- 02-Doc 02a- Annex A 1
Rapport au Conseil d’administration
1
er-2 juillet 2026
Annexe A
Thème /
Sous -thème
Situation avant le
changement
Réformes déjà mises en œuvre Résultats obtenus Prochaines étapes
1) Politiques de gestion du Secrétariat
1.1 Répertoire
et maintenance
des politiques
• Plus de 190 documents
d’orientation internes
• Pas d’archive centrale
ni de visibilité sur
l’instrument utilisé pour
la prise de décision
• Politiques faisant
double emploi
• Un répertoire des politiques
opérationnelles a été créé ; il
rassemble tous les documents
d’orientation internes dans une
archive unique pour apporter de la
transparence.
• Des évaluations externes ont été
menées pour décrire les lacunes, et
de gros efforts ont été consentis
pour réviser les principales
politiques opérationnelles, en
particulier, pour renforcer les
contrôles et les contrepoids (p. ex.
politique d’achats, politique des
ressources hum aines et autres
politiques décrites ci -dessous au
point 1.2).
•
Un plan de travail pour la
maintenance des politiques a été
lancé pour approuver, supprimer ou
• Un syst?me transparent
est désormais en place
pour superviser
l’élaboration et
l’approbation des
politiques opérationnelles
du Secrétariat ; il a
permis d’améliorer la
transparence et a rendu
l’approche d’élaboration
et d’approbation des
politiques du Secr étariat
plus cohérente.
• Il renseigne aussi plus
précisément sur les
instruments utilisés pour
la prise de décision et sur
les possibilités de
correction de trajectoire,
et réduit les
• Des ressources ont
été approuvées
pour transformer le
répertoire des
politiques en outil
numérique.
Board- 2026-Mtg- 02-Doc 02a 1
Rapport au Conseil d’administration
1er-2 juillet 2026
Rapport de la directrice exécutive
24 juin 2026
Chers·ères membres du Conseil d’administration,
Ces deux dernières années ont compté parmi les plus difficiles de l’histoire récente de
la santé mondiale, et Gavi n’a pas été épargnée par ces tensions. Pendant toute cette
période, nous avons répondu avec célérité et rigueur, en nous attachant résolument
à nous adapter à un environnement en mutation rapide.
En 2025, nous avons progressé dans un ambitieux programme, sur plusieurs fronts :
en recalibrant notre stratégie Gavi 6.0, en menant avec succès une reconstitution des
ressources, en réformant notre modèle opérationnel pour les pays, en réformant et en
rationalisant le Secrétariat, et en renforçant notre engagement externe. Je suis
heureuse de pouvoir annoncer qu’au terme du premier semestre 2026, ces efforts se
traduisent par une mise en œuvre et des résultats concrets.
Le présent rapport donne un aperçu des progrès que nous avons accomplis ces
12 derniers mois, des défis qui subsistent et des priorités à venir. Ce rapport est aussi
le premier présenté au Conseil d’administration à l’issue de la période stratégique
Gavi 5 .0/5.1 et propose à ce titre un aperçu de nos performances au regard de ces
objectifs stratégiques. Le rapport s’articule autour de quatre domaines :
• résultats au regard des objectifs stratégiques de Gavi 5.0/5.1 ;
• état de la reconstitution des ressources de Gavi 6.0 ;
• progrès du programme de transformation, de la mise en œuvre de Gavi 6.0, et
de réforme Gavi Leap;
• principaux défis et questions que le Conseil d’administration doit examiner.
Nous avons à nouveau des raisons d’envisager l’avenir avec confiance. Un Secrétariat
allégé et plus agile concrétise les réformes Gavi Leap, tandis qu’une Alliance qui a
redéfini et renouvelé les rôles et responsabilités de ses partenaires contribuera à
mieux cibler nos efforts collectifs. Parallèlement, notre modèle opérationnel réformé
pour les pays accélère l’exécution de la stratégie Gavi 6.0 recalibrée. Portés par une
dynamique solide, nous abordons cette nouvelle phase en nous appuyant fermement
sur l es accomplissements de la période Gavi 5.1 et en nous concentrant sur
l’obtention d’un impact plus marqué pour les pays et les communautés que nous
desservons.
Ces progrès témoignent du dévouement du personnel du Secrétariat et du leadership
de mon équipe de direction et, bien sûr, de la contribution essentielle des partenaires
de l’Alliance Gavi. Je veux leur exprimer ma profonde gratitude pour leur engagement
envers la mission de Gavi et pour faire de Gavi Leap une réussite. Je tiens également
02b Annex A Technical report on Gavi 50 51 indicators pdf
Board-2026-Mtg- 02-Doc 02-Annex A 1
Report to the Board
1-2 July 2026
Annex A: Technical report on Gavi 5.0/5.1 indicators
This is a technical report providing definitions of and progress against Mission and
Strategy Goal indicators in the Gavi 5.0/5.1 measurement framework. The technical
report is populated based on available data and updated bi -annually. The newly
available data for 2025 included in this report relates to Mission Goal M1 and Strategy
Goals S1.4, S3.1, S3.3, and SG4. The remaining indicators will be updated in
September 2026.
Note on target trajectories:
In the below graphs, the dotted lines represent the projected annual trajectory that
was forecasted when we set 2025 targets with the PPC/Board in May 2021; our
assumption was that coverage would return to 2019 coverage levels in 2021, with the
exception of India which would take until 2022. This was noted in a footnote in the
PPC paper on the Gavi 5.0 Measurement Framework at the time (PPC -2021- Mtg-2 -
Doc 04):
To account for COVID -19- related disruptions and recovery, it is assumed that
vaccine coverage returns to 2019 levels by 2021, with the exception of India,
which we assume returns to 2019 levels in 2022 and sub- national three doses
of pneumococcal conjugate vaccine (PCV3) scale up takes an additional year.
Gavi 5.0 Mission Indicators
M.1: Under -five mortality rate – Updated April 2026
By increasing access to immunisation and
enabling equal access to new and
underused vaccines, Gavi support is
contributing to the reduction in under-five
deaths from vaccine- preventable
diseases.
The under - five mortality rate in the 57
lower-income countries supported by Gavi
fell from 5 9 to 52.6 deaths per 1,000 live
births between 2019 and 2024 – a n 11 %
reduction from baseline. We have thus
exceeded
our Mission target of a 10%
reduction by 2025. Estimates for 2025 will
be available in early 2027.